Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q2 2017 · 10-Q
Revenue$335.52K$335.52K+197.8% vs Q2 2016 Net Income-$8.80M-$8.80MN/M vs Q2 2016 EPS Diluted-$0.51-$0.51N/M vs Q2 2016 Operating Income-$8,876,965N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,721,546N/M Margins · derivedOperating margin-2645.7%+7534.0 pt vs Q2 2016
Net margin-2624.1%+7459.8 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 2, 2017 · 33 d after period end